Oncology

recent-pharma-news-updates-for-adarx-ixaka-novocure-vor-biopharma

Notizia - Recent Pharma, Healthcare and Biotech Happenings

ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System

Explore More...

Non-Hodgkin Lymphoma: “Malignant Growth of White Blood Cells”

Chemotherapy-Induced Nausea and Vomiting Side effects

Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world’s most pricey drugs

The Snippet: Targeting metabolism in Renal Cell Carcinoma

Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill

Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout talks

Dengvaxia study; Opdivo racks up; FDA issues plant; Teva’s Rimsa fraud; Mission bags Fox grant

CRISPR finds faults in previous researches

Therapeutics

Valeant’s asset-sale; Sanofi coughs up $19.8M; Sanofi’s Genzyme; India’s Alkem; GSK’s inhalers

DNA typos to blame for most Cancer Mutations

Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings

AKT Inhibitors: A potential Cancer Immunotherapy Target

Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns

GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss

Colorectal Cancer Awareness Month

New biomarkers improve standard screening in Pancreatic Cancer

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader